Although prior studies have reported a positive correlation between glycosylation status of BCRP and drug resistance (poor therapeutic outcomes) in cancers, for instance (28) reported significant reversal of MDR phenotypes in ovarian and colorectal cancers following chemical inhibition of BCRP glycosylation, Sia remained uninvestigated. This evidence concerns the gene ABCG2 and colorectal cancer.